Oxidative stress and interleukin-6 secretion during the progression of type 1 diabetes

被引:20
|
作者
Reis, Janice Sepulveda [1 ]
Veloso Amaral, Clara Araujo [1 ]
Oliveira Volpe, Caroline Maria [1 ]
Fernandes, Jamille Silveira [1 ]
Borges, Erica Abreu [1 ]
Isoni, Camila Armond [1 ]
Ferreira dos Anjos, Paula Martins [1 ]
Nogueira Machado, Jose Augusto [1 ]
机构
[1] Hosp Santa Casa Belo Horizonte, Nucleo Pesquisa & Posgrad, Belo Horizonte, MG, Brazil
关键词
Type; 1; diabetes; disease progression; oxidative stress; plasma antioxidant status; GLYCEMIC CONTROL; CHILDREN; MELLITUS; ONSET; ACTIVATION; CYTOKINES; MEDIATORS; PLASMA; PHASE; IL-6;
D O I
10.1590/S0004-27302012000700006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To evaluate inflammatory, oxidizing, and reducing responses during the progression of type 1 diabetes mellitus (T1DM) in patients without chronic complications. Subjects and methods: Plasma antioxidant status, reactive oxygen species (ROS), and interleukin-6 (IL-6) were measured in 42 patients with T1DM and in 24 healthy subjects. Results: Significant increases were detected in the median values of ROS and IL-6 in patients with T1DM compared with healthy subjects (ROS similar to 4,836 vs. 2,036 RLU/min, respectively; P<.05: IL-6 similar to 14.2 vs. 9.7 pg/mL, respectively; P=.002). No significant between-group differences (P>0.05) were observed in oxidizing responses or in IL-6 concentrations when diabetic patients were grouped according to time after diagnosis (0 - 10, 10 - 20 and > 20 years). Plasma antioxidant responses were similar in patients with T1DM and in healthy subjects. Conclusions: Our results demonstrate that oxidizing and inflammatory responses are increased at the onset of T1DM, but remain unchanged during disease progression. These findings suggest that functional changes involved in diabetic complications may commence in the first years after diagnosis. Arq Bras Endocrinol Metab. 2012;56(7):441-8
引用
收藏
页码:441 / 448
页数:8
相关论文
共 50 条
  • [1] Interleukin-6 modulates oxidative stress produced during the development of cisplatin nephrotoxicity
    Mitazaki, Satoru
    Hashimoto, Midori
    Matsuhashi, Yui
    Honma, Shigeyoshi
    Suto, Miwako
    Kato, Naho
    Nakagawasai, Osamu
    Tan-No, Koichi
    Hiraiwa, Kouichi
    Yoshida, Makoto
    Abe, Sumiko
    LIFE SCIENCES, 2013, 92 (12) : 694 - 700
  • [2] Induction of oxidative stress and endothelial dysfunction by interleukin-6 via angiotensin type 1 receptor overexpression
    Wassmann, S
    Stumpf, M
    Strehlow, K
    Boehm, M
    Nickenig, G
    EUROPEAN HEART JOURNAL, 2003, 24 : 128 - 128
  • [3] Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor
    Wassmann, S
    Stumpf, M
    Strehlow, K
    Schmid, A
    Schieffer, B
    Böhm, M
    Nickenig, G
    CIRCULATION RESEARCH, 2004, 94 (04) : 534 - 541
  • [4] SEX DIFFERENCES IN INTERLEUKIN-6 STRESS RESPONSES IN PEOPLE WITH TYPE 2 DIABETES
    Panagi, Laura
    Poole, Lydia
    Hackett, Ruth A.
    Steptoe, Andrew
    PSYCHOSOMATIC MEDICINE, 2019, 81 (04): : A127 - A127
  • [5] Sex differences in interleukin-6 stress responses in people with Type 2 diabetes
    Panagi, Laura
    Poole, Lydia
    Hackett, Ruth A.
    Steptoe, Andrew
    PSYCHOPHYSIOLOGY, 2019, 56 (06)
  • [6] Altered kinetics of interleukin-6 and other inflammatory mediators during exercise in children with type 1 diabetes
    Rosa, Jaime S.
    Oliver, Stacy R.
    Mitsuhashi, Masato
    Flores, Rebecca L.
    Pontello, Andria M.
    Zaldivar, Frank P.
    Galassetti, Pietro R.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2008, 56 (04) : 701 - 713
  • [7] Interleukin-6 Is Required for Pancreatic Cancer Progression by Promoting MAPK Signaling Activation and Oxidative Stress Resistance
    Zhang, Yaqing
    Yan, Wei
    Collins, Meredith A.
    Bednar, Filip
    Rakshit, Sabita
    Zetter, Bruce R.
    Stanger, Ben Z.
    Chung, Ivy
    Rhim, Andrew D.
    di Magliano, Marina Pasca
    CANCER RESEARCH, 2013, 73 (20) : 6359 - 6374
  • [8] Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus
    S. Kado
    T. Nagase
    N. Nagata
    Acta Diabetologica, 1999, 36 : 67 - 72
  • [9] Circulating levels of interleukin-6, its soluble receptor and interleukin-6/interleukin-6 receptor complexes in patients with type 2 diabetes mellitus
    Kado, S
    Nagase, T
    Nagata, N
    ACTA DIABETOLOGICA, 1999, 36 (1-2) : 67 - 72
  • [10] Interleukin-6: a possible inflammatory link between vitiligo and type 1 diabetes
    Farhan, J.
    Al-Shobaili, H. A.
    Zafar, U.
    Al Salloom, A.
    Meki, A-R.
    Rasheed, Z.
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2014, 71 (04) : 151 - 157